An observational study in Breast Carcinoma, sponsored by OHSU Knight Cancer Institute. Enrolling by invitation at 1 site in United States. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by OHSU Knight Cancer Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · OHSU Knight Cancer Institute.
Among the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, this one is one of 3 that started in 2022, is one of 5 observational ones, and was the 24th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18–100
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 74 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 2
First in 2001; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,141 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 37 across the 24 interventional studies, 98 across the 5 observational. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
1 of the studies in Breast Neoplasms by OHSU Knight Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04993313OHSU Knight Cancer InstituteStandard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study collects information to implement MammoScreen for Breast Cancer Screening and Referrals. MammoScreen is a risk assessment questionnaire that identifies individuals at average and increased risk for breast cancer and guides their screening decisions.
PRIMARY OBJECTIVES:
I. Uptake of MammoScreen (the proportion of women who enroll and use MammoScreen, also referred to as Reach.
II. Identification of women with above-average risk for breast cancer by MammoScreen integrated with the electronic health record (EHR).
SECONDARY OUTCOMES:
I. Rates of mammography screening referral. II. Screening completed and mammography results stratified by risk category. III. Among those who meet criteria, genetic counseling referral, visit completed and genetic test done.
OUTLINE:
CLINICAL STAFF: During development some clinical team members will participate in usability testing (up to 30 minutes) of the electronic health record interface with MammoScreen. Some participants will undergo training sessions of about 20 minutes, then participate in interviews lasting up to 30 minutes at baseline prior to MammoScreen launch. Clinical staff also participate in interviews up to 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase about six months after the last reminders are sent.
PATIENTS: Patients (enrolled from OHSU IMC) participate in interviews lasting up to 1 hour. Patients medical records are reviewed. Patients will be invited via MyChart to use the MammoScreen. Reminders will be sent via MyChart to non-respondents at 2 and 4 weeks. Patients will use MammoScreen one time right after enrollment. Some patients may also participate in interviews up to 1 hour each during years 3-5.
Women between the ages of 40 and 74
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants undergo training sessions over 20 minutes and participate in interviews over 30 minutes at baseline, prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase, about six months after the last reminders are sent.
Other: Electronic Health Record Review · Other: Interview · Other: Survey Administration · Other: Training and Education
Patients participate in interviews up to 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
Other: Electronic Health Record Review · Other: Interview · Other: Media Intervention
Health record reviewed
Participate in interview
Use MammoScreen
Complete survey
Undergo training
Uptake of MammoScreen
Defined as the proportion of women who enroll and use MammoScreen. Proportions of invitations for newly eligible women and uptake of MammoScreen during the maintenance period, overall and by clinical team, will be characterized along with 95% exact confidence intervals.
Time frame: Up to 5 years
Number of women with above-average risk for breast cancer identified by MammoScreen integrated with the electronic health record
Time frame: Up to 5 years
Rates of mammography screening referral
Time frame: Up to 5 years
Screening completed
The proportions of patients who open, and complete MammoScreen and 95% confidence intervals will be calculated. Demographic and clinical characteristics of patients who complete MammoScreen versus those who do not will be compared using a two-sample t-test or chi-square test as appropriate. Variation in completing MammoScreen by patient (e.g., age) and provider characteristics (e.g., panel size) will be explored.
Time frame: Up to 5 years
Mammography results
Will be stratified by risk category. Will be analyzed similarly using proportions and 95% confidence intervals, and a regression model if allowed by data.
Time frame: Up to 5 years
Number of above average risk MammoScreen users who received a genetic counseling referral
Will be analyzed similarly using proportions and 95% confidence intervals, and a regression model if allowed by data.
Time frame: Up to 5 years
Number of above average risk MammoScreen users who completed a genetic counseling visit
Time frame: Up to 5 years
Number of above average risk MammoScreen users who had a genetic test done
Time frame: Up to 5 years
Ran from Sep 2022 to primary completion in Apr 2025, 31 months.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 31 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OHSU Knight Cancer Institute →